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INTRODUCTION
Current treatment options for severe mood disorders are limited by the slow time course of change in suicidal thoughts. For instance, in major depressive disorder (MDD) patients receiving thrice-weekly electroconvulsive therapy, suicidal thoughts persisted in 62% of patients after 1 week of treatment and 39% after 2 weeks (1) . Conventional antidepressant treatment produced slower and less robust response in elderly MDD patients with moderate-to-high suicide risk than in non-suicidal patients (2) .
Treatment of acute suicidality is further constrained by inaccuracies in patients' explicit reports of suicidal thoughts (3, 4) . The Implicit Association Test (IAT)(5) may be useful as a behavioral measure of suicidal cognition, as the task is reliable (6) and resistant to attempts to intentionally control its outcome (7) . Furthermore, when socially "taboo" cognitions are assessed (e.g., prejudicial attitudes), the IAT is a superior predictor of future behavior relative to explicit measures (8) . IAT variants assessing suicide-and self-injury-related cognition have shown promise in discriminating between self-injurious and non-injurious adolescents (9) , suicidal and non-suicidal adolescents (3) , and adult suicide attempters and non-attempters presenting to a psychiatric emergency department (10) .
Early evidence suggests that a single subanesthetic dose of intravenous (IV) ketamine, a glutamate-modulating agent, acutely reduces depressive symptoms in approximately 70% of MDD patients 24 hours after infusion (11) (12) (13) . We tested ketamine's impact on suicidal cognition in a sample of adults with treatment-resistant depression (TRD). We hypothesized that ketamine would yield rapid, correlated reductions in explicit and implicit suicidal indices. Furthermore, we expected that rapid initial reductions in explicit suicidality would be sustained through repeated ketamine infusions.
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MATERIALS AND METHODS
Twenty-six TRD patients were recruited via media advertisement or clinician referral.
Treatment-resistance was defined as two or more failed, adequate antidepressant trials in the current episode, as determined by the Antidepressant Treatment History Form (14) . DSM-IV-TR diagnoses of MDD were established by SCID-I/P interview. Eligible participants had moderateto-severe depression (Inventory of Depressive Symptomatology score ≥32) (15) ; were psychotropic medication-free for ≥2 weeks prior to infusion (4 weeks for fluoxetine); free of substance abuse/dependence for ≥6 months; denied lifetime use of ketamine and PCP; had no lifetime history of psychotic disorder, mania or hypomania; and had no clinically unstable medical or neurological conditions. Patients whom research team psychiatrists deemed unsafe for study participation due to highly active suicidality were excluded.
Patients were admitted to a private hospital room for a 28-hour period for racemic ketamine hydrochloride infusion (0.5 mg/kg diluted in saline, administered over 40 minutes by IV pump (12) ) and cardiorespiratory monitoring. Patients were assessed for depressive symptoms 150 minutes prior to, and 24-hours following, infusion using the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-administered measure that includes a single suicidality item (Table 1)(16). MADRS raters held graduate degrees and achieved high inter-rater reliability both during training and when co-rating a random sample of videotaped study interviews (ICC's≥0.96). The timeframe for post-infusion MADRS was modified to reflect the period since last assessment. Ketamine's antidepressant effects in this sample (not including suicidality analysis) have been reported previously (13) .
A subset of patients (n=12) 1 completed the IAT and the 21-item self-report Beck Scale for Suicidal Ideation (BSI)(17) at baseline. Ten patients repeated these measures 24-hours post-
A distinct subset of single-dose ketamine responders (n=10) 3 enrolled in a subsequent study of repeated-dose IV ketamine. Detailed methods, tolerability, and antidepressant effects will be reported separately (18). Following a Day 1 infusion identical to that described above, patients were assessed for 24-hour antidepressant response (MADRS≤50% of baseline score).
Responders (9/10 participants) then received up to 5 additional infusions ( Days 3, 5, 8, 10, 12) identical to the first, except that patients were assessed and discharged 4-hours post-infusion. 
Implicit Association Test (IAT)
Two recently developed variants of the IAT (IAT-Death, assessing the strength of association between words related to "Death" and "Me"; IAT-Escape, assessing associations between "Escape" and "Me") were selected based on the hypothesis that individuals contemplating suicide would be characterized by greater self-identification with death (relative to life) and escape (relative to stay). Preliminary evidence suggests these associations are stronger in suicide attempters than non-attempters (10) . IATs were administered and scored in accordance with recommended procedures (19) and followed a design described previously (9)(Supplement B). "Escape=Me" and "Death=Me" D-scores were calculated for each 1 IAT and BSI data were collected from patients enrolled during the latter half of the enrollment period only 2 Time constraints prevented post-infusion data collection in 2 patients 3 In the TRD subsample completing baseline IATs (n=12), stronger "Escape=Me" implicit associations were associated with greater MADRS-SI scores (rho=.60; p=.04), and marginally Price et al. Explicit and Implicit Suicidality   7 with SI composite scores (rho=.57; p=.052), but not with non-suicide-related depression severity (MADRS-total nonSI : rho=.24; p=.46). Baseline "Death=Me" associations were unrelated to other measures (ps >.34). In patients who repeated the measures 24-hours post-infusion (n=10), there was a reduction in "Escape=Me" associations (t 9 =3.76; p=.006; d=1.37) (Figure 2 ) and in BSI (t 9 =3.15; p=.012) and MADRS-SI (t 9 =5.24; p<.001). "Death=Me" associations were not significantly changed (t 9 =.658; p=.52). "Escape=Me" reductions were correlated with reductions in BSI (r=.65; p=.042), SI composite (r=.64; p=.048), and MADRS-SI at the trend level (r=.57; p=.09), but not with MADRS-total nonSI changes (r=-.03; p=.94). "Death=Me" changes showed a trend-level association with BSI changes only (r=.60; p=.06). Most zero-order correlations were maintained or increased after controlling for change in MADRS-total nonSI and baseline SI composite ( Table 4 ).
Effects of Ketamine on
In patients who subsequently enrolled in the repeated-dose ketamine study (n=10), the first infusion again significantly reduced MADRS-SI scores (2.8-point mean decrease; t 9 =5.47, p<.001; d=2.17), with 90% of patients receiving a 24-hour rating of 0 (Table 3; Figure 1) . Acute reductions were maintained throughout the 12-day treatment period by the 9 patients receiving repeated infusions (baseline-to-day-12 mean decrease=2.89; t 8 =5.12, p=.001; d=2.42), with no patient scoring >2 at any post-baseline assessment (before and after each infusion).
DISCUSSION
These preliminary findings support the premise that a single subanesthestic dose of IV ketamine has rapid effects on suicidal cognition in TRD, and that acute improvements in suicidality can be sustained through repeated ketamine infusions. Confidence intervals for MADRS-SI suggested moderate to very large effects, despite small sample sizes.
An IAT assessing the association between 'Me' and 'Escape' was related to explicit suicidal ideation at baseline and showed sensitivity to therapeutic change, an important criterion if the IAT is to have utility as a clinical assessment tool. Associations between 'Me' and 'Death' did not change as predicted, suggesting that the implicit representation of suicide in TRD might more closely relate to the concept of escape than to death itself. his claim to any royalties and will not benefit financially if ketamine is approved for this use.
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Supplement 2
The Implicit Association Test (IAT) rests on the assumption that it is easier to map two concepts onto a single behavioral response (e.g., left key press) when they are closely associated than when they are loosely associated. The two IATs (IAT-Death; IAT-Escape) were completed in counterbalanced order on a Dell laptop computer running Inquisit (Millisecond Software, Seattle, WA). Participants were instructed to classify stimuli appearing at the center of the screen by pressing the "e" key for words belonging to categories on the left of the screen and the "i" key for words belonging to categories on the right. In the IAT-Death, a series of words related to death (suicide, die, dead, deceased, lifeless) or life (alive, live, survive, thrive, breathing) were presented in random order, intermixed with a series of self-relevant (I, Myself, My, Mine, Self) or other-relevant (They, Them, Their, Other, Theirs) words. Category labels ("Death," "Life," "Me," "Not Me") remained in the upper left and right corners of the screen throughout the task (Supplemental Figure 2) . 
Supplemental Figure 2. Schematic of Implicit Association Test
